Ahmed Galal
A5101990764- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Biomedical Ethics and Regulation
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Bone and Joint Diseases
- Advancements in Semiconductor Devices and Circuit Design
- Eosinophilic Disorders and Syndromes
- Neutropenia and Cancer Infections
- Hemoglobinopathies and Related Disorders
- Biosimilars and Bioanalytical Methods
- Radio Frequency Integrated Circuit Design
- Multiple Myeloma Research and Treatments
- Soft tissue tumor case studies
- Protein Degradation and Inhibitors
- MicroRNA in disease regulation
- Parvovirus B19 Infection Studies
- Lung Cancer Treatments and Mutations
- Circular RNAs in diseases
- Health and Well-being Studies
Duke Medical Center
2019-2024
Duke University
2017-2024
Atlantic Health System
2024
Health Net
2024
Cedars-Sinai Medical Center
2024
Duke University Health System
2023
Duke Cancer Institute
2021
Alexandria University
2017
Cairo University
2017
Avera McKennan Hospital & University Health Center
2013
On the basis of results ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes patients treated brexu-cel as standard therapy.
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis 189 patients relapsed/refractory ALL treated brexu-cel. Over half the received InO before brexu-cel (InO exposed). InO-exposed were more heavily pretreated (P = .02) and frequently had active marrow disease apheresis .03). Response rate toxicity profile after comparable...
Early absolute lymphocyte count (ALC) has become an important end point for engraftment in patients undergoing autologous peripheral stem cell transplantation (APSCT). In this retrospective study, we evaluate the prognostic significance of early recovery ALC (≤0.5 cells × 109/l on or before day 15) following APSCT predicting transplant outcome 72 with lymphoproliferative disorders, including non-Hodgkin's lymphoma (n = 30), Hodgkin's 8) and multiple myeloma 34). The median quantities CD34+...
7001 Background: In October 2021, brexucabtagene autoleucel (brexu-cel) became the first CAR-T cell therapy to receive FDA approval for adults (≥18 yrs) with relapsed/refractory (r/r) B-ALL. Approval was based on Phase II results of ZUMA-3, a single-arm, open-label, multicenter trial which reported 55 treated patients CR/CRi achieved in 71%; cytokine release syndrome (CRS) and neurologic toxicities occurred 89% (grade 3-4, 24%) 60% 25%), respectively. Here, we report outcomes 76 r/r B-ALL...
Abstract Older AML patients have low remission rates and poor survival outcomes with standard chemotherapy. Microtransplantation (MST) refers to infusion of allogeneic hematopoietic stem cells without substantial engraftment. MST has been shown improve clinical compared chemotherapy alone. This is the first trial reporting on broad correlative studies define immunologic mechanisms action in older patients. newly diagnosed were eligible for enrollment, receiving induction cytarabine (100...
Chronic myeloid leukemia can be effectively treated with BCR-ABL1 tyrosine kinase inhibitors. However, mutations develop and cause secondary resistance to these For each of the available inhibitors, certain are known associated resistance, although most that confer one inhibitor remain sensitive or more other patients displaying poor response loss frontline treatment, possibility they have developed a new mutation must considered, selection second-line treatment consider patient's mutational...
Primary CNS lymphoma is a rare form of extranodal Non Hodgkin's (NHL). Combination chemotherapy followed by whole brain radiation has remained the cornerstone therapy. Relapse rates are high and delayed neurotoxicity, with severe cognitive dysfunction, significant. High dose autologous stem cell rescue been used as consolidation in newly diagnosed patients salvage times relapse. This approach considered promising.
There are limited data on the impact of intensity conditioning QOL in patients undergoing alloHCT. We undertook a prospective study to evaluate outcomes and with myeloid malignancies alloHCT using MY or RIC. 115 were enrolled from Jan 2005 Sep 2008 no significant differences observed two cohorts at 1-year (abstract submitted separately). Of patients, 105 (91%) (MY, 44; RIC, 61) consented participate assessments baseline, day30, day100, day180 day365. was assessed by following measures:...
e19502 Background: CAR T cell therapy can provide sustained remissions in patients with hematologic malignancies. However, some are resistant to or relapse after therapy. is complicated by cytokine release syndrome (CRS) and immune effector cell-associated (ICANS). There an unmet need understand types functions correlation clinical outcomes. Methods: Patients malignancies treated commercial products were enrolled the study. Blood samples collected at day -7 before lymphodepletion, 0...